Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme

NCT00054496 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

73

Enrollment

OTHER

Sponsor class

Conditions

Brain and Central Nervous System Tumors

Interventions

DRUG: erlotinib hydrochloride

Sponsor

The Cleveland Clinic